Exclusive Summary

• Solves a Critical Safety Hurdle: To date, zero clinical cases of Interstitial Lung Disease (ILD) have been reported, addressing the primary safety risk of the market leader, Enhertu, and positioning it as a potentially safer treatment option.
• Demonstrates Potential Best-in-Class Efficacy: Achieved an impressive 61.5% ORR in HER2-low breast cancer, with preliminary data suggesting superiority over Enhertu and the potential to become a new efficacy benchmark.
• Innovative Mechanism with Broad Pipeline-in-a-Product Value: Features a unique biparatopic ADC design effective against HER2-low and resistant tumors, and is already in multiple Phase 3 trials across various cancers (breast, colorectal, etc.).

Asset Materials

Contact Us for Full Materials